NCT02922946 is a Phase 1 clinical trial of Entinostat in Volunteers, sponsored by Syndax Pharmaceuticals.

Who is sponsoring NCT02922946?

NCT02922946 is sponsored by Syndax Pharmaceuticals.

What drugs are being tested in NCT02922946?

Interventions in NCT02922946: Entinostat.

What condition does NCT02922946 study?

NCT02922946 studies Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers.

Is NCT02922946 still recruiting?

NCT02922946 is currently completed. Last updated 16 August 2018.

Last reviewed 2018-08-16 · How we verify

NCT02922946

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat

Completed Phase 1 Last updated 16 August 2018

What this trial tests

Phase 1 trial testing Entinostat in Volunteers in 47 participants. Completed in 26 June 2017.

Timeline

11 October 2016

Primary endpoint
20 May 2017

26 June 2017

Quick facts

Lead sponsor	Syndax Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	47
Start date	11 October 2016
Primary completion	20 May 2017
Estimated completion	26 June 2017
Sites	1 location across United States

Drugs / interventions tested

Entinostat — full drug profile →

Conditions studied

Volunteers — all drugs for Volunteers →
Healthy Volunteers — all drugs for Healthy Volunteers →
Human Volunteers — all drugs for Human Volunteers →
Normal Volunteers — all drugs for Normal Volunteers →

Sponsor

Syndax Pharmaceuticals — full company profile →

Who can join

Adults 19 to 55, any sex, with Volunteers or Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives of this study are to evaluate the effect of the timing of a moderate-fat meal on the single dose pharmacokinetics of entinostat and to evaluate the safety and tolerability of entinostat under fed and fasting conditions in healthy adult subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
Reviewing the role of healthy volunteer studies in drug development.
Karakunnel JJ, Bui N, Palaniappan L, Schmidt KT, et al · · 2018 · cited 33× · PMID 30509294 · DOI 10.1186/s12967-018-1710-5

Verify or expand the search:

Other trials of Entinostat

Trials testing the same drug.

NCT07441486 — A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment · Phase 2 · not yet recruiting
NCT07261592 — Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer · Phase 1, PHASE2 · not yet recruiting
NCT05898828 — Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Th · Phase 1, PHASE2 · withdrawn
NCT05053971 — Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
NCT04708470 — A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, · Phase 1, PHASE2 · active not recruiting

Other recruiting trials for Volunteers

Currently open trials in the same condition.

NCT07319039 — Breathlessness Patterns in Patients With Cancer, COPD and Heart Failure: an fMRI Feasibility Study · recruiting
NCT04256330 — Cardiometabolic Health and Inflammatory Resolution · recruiting

Other Syndax Pharmaceuticals trials

Trials by the same sponsor.

NCT05731947 — Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors · Phase 1, PHASE2 · completed
NCT05406817 — Study of Radiolabeled Revumenib in Adults With Acute Leukemia · Phase 1 · completed
NCT05326516 — A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia · Phase 1 · completed
NCT04415073 — A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 · Phase 2 · terminated
NCT04065399 — A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02922946 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Syndax Pharmaceuticals
Last refreshed: 16 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02922946.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing